Abstract

Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice Remain Comparable to the Outcomes Reported in the Phase 3 Tourmaline-MM1 Study
Evangelos Terpos ...
Blood | VOL. 134
Evangelos Terpos, et. al.Evangelos Terpos ...
13 Nov 2019
Selinexor in Combination with Carfilzomib and Dexamethasone, All Once Weekly (SKd), for Patients with Relapsed/Refractory Multiple Myeloma
... Muhamed Baljevic
Blood | VOL. 136
, et. al. ... Muhamed Baljevic
05 Nov 2020
Selinexor-Based Regimens in Patients with Multiple Myeloma after Prior Anti-B-Cell Maturation Antigen Treatment
Jatin J Shah ... Heather J Sutherland
Blood | VOL. 138
Jatin J Shah, et. al.Jatin J Shah ... Heather J Sutherland
05 Nov 2021
Efficacy of Daratumumab in Combination with Standard of Care Regimens in Lenalidomide-Exposed or -Refractory Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Analysis of the Castor, Pollux, and MMY1001 Studies
Pieter Sonneveld ...
Blood | VOL. 132
Pieter Sonneveld, et. al.Pieter Sonneveld ...
29 Nov 2018
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Increased risk of venous thromboembolism in young and middle-aged individuals with hereditary angioedema: a family study.
Linda Sundler Björkman ... Bengt Zöller
Blood | VOL. -
Linda Sundler Björkman, et. al.Linda Sundler Björkman ... Bengt Zöller
17 May 2024
Mutational profile of previously treated chronic lymphocytic leukemia patients progressing on acalabrutinib or ibrutinib.
Jennifer A Woyach ... Veerendra Munugalavadla
Blood | VOL. -
Jennifer A Woyach, et. al.Jennifer A Woyach ... Veerendra Munugalavadla
16 May 2024
Outcomes of younger patients with mantle-cell lymphoma experiencing late relapse (>24 months): the LATE-POD study.
Chiara Malinverni ... Carlo Visco
Blood | VOL. -
Chiara Malinverni, et. al.Chiara Malinverni ... Carlo Visco
16 May 2024
Fusion Harboring Mast Cells Can Explain Molecular Positivity in Flow Cytometric MRD Negative Core Binding Factor AML.
Jacqueline A Cook ... Andrew J Menssen
Blood | VOL. -
Jacqueline A Cook, et. al.Jacqueline A Cook ... Andrew J Menssen
15 May 2024
View more papers